The Limited Times

Now you can see non-English news...

Covid-19: United States authorizes resumption of vaccination with Johnson & Johnson

2021-04-24T21:50:18.470Z


Janssen's serum was suspended in mid-April after the discovery of rare cases of thrombosis. US health authorities gave the green light on Friday to resume vaccination with Johnson & Johnson's serum in the United States, suspended on April 13 after rare cases of thrombosis. To discover Covid-19: instructions for use of self-tests " The use of Janssen's Covid-19 vaccine is expected to resume in the United States, " the Centers for Disease Control and Prevention (CDC) and the US drug age


US health authorities gave the green light on Friday to resume vaccination with Johnson & Johnson's serum in the United States, suspended on April 13 after rare cases of thrombosis.

To discover

  • Covid-19: instructions for use of self-tests

"

The use of Janssen's Covid-19 vaccine is expected to resume in the United States,

" the Centers for Disease Control and Prevention (CDC) and the US drug agency, the FDA, said in a statement. that the benefits of the vaccine outweighed the risks in people 18 years of age and older.

To read also: AstraZeneca and Janssen "essential" for the vaccination campaign, according to the Ministry of Health

The break in the use of the vaccine developed by the American laboratory had been decided to investigate several cases of women who developed serious cases of blood clots in association with low levels of platelets after their injection.

The FDA and CDC are confident that this vaccine is safe and effective in preventing Covid-19,

” the two agencies said.

"For now, the available data suggests that the risk" of thrombosis "

is very low, but the FDA and the CDC will remain vigilant and will continue to investigate this risk

", according to the text.

Health care personnel administering the vaccine as well as those receiving it "

should review the information sheet

" on the vaccine, "

which has been updated to include information on the risk of this syndrome, which is is produced in a very small number of people who have received the Janssen vaccine

”.

Earlier Friday, experts from the US health authority recommended resuming vaccination with Johnson's serum.

Read also: United States: the FDA stops the production of Johnson & Johnson in a factory

The company's scientific director, Paul Stoffels, said he was

"grateful

" for the decision of the experts, according to him "

an essential step towards the continuation of urgently needed vaccinations, in a safe environment, for millions of people. in the United States

”.

The Johnson & Johnson vaccine has already been given to 7.98 million people in the United States.

According to data presented Friday, out of 3.99 million women vaccinated, 15 developed severe cases of blood clots, and three died.

Thirteen of them were under 50 years old, the other two were between 50 and 64 years old.

There have been no known cases in vaccinated men.

Some experts notably highlighted on Friday the benefits of this single-dose vaccine, which can be stored in refrigerators and more easily reach vulnerable groups, faced with the very rare risks of thrombosis, which can have devastating neurological consequences even when they are not. deadly.

"It would be detrimental to do away with a vaccine which can be administered as a single dose and which has the preference of the Hispanic community

," said Dr. Jose Romero, head of the expert committee.

The J&J vaccine has been shown to be 66% effective in preventing moderate to severe forms of Covid-19, according to clinical trials conducted on approximately 40,000 people aged 18 or over in several countries around the world.

Although the link with the vaccine has not been demonstrated, scientists consider it to be the "

probable cause

" of the phenomenon of thrombosis, also detected with the AstraZeneca vaccine.

Johnson & Johnson and AstraZeneca technology uses an adenovirus as a vector, such as the Russian Sputnik V and Chinese CanSino vaccines.

Source: lefigaro

All tech articles on 2021-04-24

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.